Biotech | Digitech | Medtech | Fintech
Welcome to Kinled, a forward-thinking family office which retains the assets held by the esteemed Anglo-Austrian Aisher Family through direct investments in defensible ventures emerging from Life Science and Digital Technology sectors.
In 1924, the Aisher family founded Marley, which they developed into a group of innovative manufacturing and retail businesses in the concrete building materials, plastics, automotive components, and retail industries.
Over 75 years, the family expanded the business to incorporate more than 13,000 workers in 59 countries.
Following Sir Owen Aisher’s death, the family and Kinled Holding Limited sold their participation when the company was acquired for $600M in 1999
Owen Aisher Sr
At the time the company was founded – 1924
Kinled made additional investments in the 1970s, including shareholdings in General Shale, one of the largest brick manufacturers in the United States, which was acquired by Wienerberger in 1999 for $260M, and MDL Marinas, today Europe’s largest marina group, which was sold onto the London Stock Exchange in 1985.
Over the past 30 years, Patrick Aisher has built a portfolio of over 150 Direct investments, had over 50 successful exits (including 20 via IPO) and co-invested alongside renouned VC firms and Family offices.
Company President Sir Owen Aisher & Chairman Dr. Jack Aisher
Celebrating the company's 50th Anniversary – 1974
Celebrating 25 years as Chairman – 2022
Now, for the first time, we’re inviting private investors to join us in developing academic / scientific projects and emerging technologies.
• ETH Zürich • Bern • Fribourg • Geneva • Lausanne
• Vienna • Innsbruck • Graz
• Boston • Cambridge • Harvard • Houston • MIT • Michigan • New York • Northeastern • San Diego • San Francisco • Stanford
In Europe, Kinled portfolio firms were created with technology from universities such as Aix-Marseille, Amsterdam, Barcelona, Helsinki, Linköping, London, Paris, Pecs, and Utrecht.
How We Invest
Kinled Holding and the Aisher Family have long believed in fostering academic projects to become fully-fledged commercial businesses.
We are exceptionally proud to have funded early-stage businesses from some of the most prestigious universities in the world, including:
Our unwavering dedication to Life Sciences includes the dynamic landscape of the MedTech industry, where we’ve invested in medical devices and healthcare services sectors. Combined with BioTech, this constitutes over 50% of our portfolio.
Key Holdings Include:
In digital technologies, we invest in SaaS-enabled networks and marketplaces, where technology can democratise markets and provide consumers with a greater choice of services.